Planned Interim Analysis of a Phase 2 Study of Loncastuximab Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma (LOTIS-3)

被引：12

作者：

Carlo-Stella, Carmelo ^{[1
,2
]}

Zinzani, Pier Luigi Luigi ^{[3
,4
]}

Janakiram, Murali ^{[5
]}

Dia, Vivian ^{[6
]}

He, Xiaomin ^{[6
]}

Ervin-Haynes, Annette ^{[6
]}

Depaus, Julien ^{[7
]}

机构：

[1] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[2] IRCCS Humanitas Res Hosp, Dept Hematol & Oncol, Milan, Italy

[3] Univ Bologna, IRCCS Azienda Osped, Ist Ematol Seragnoli, Bologna, Italy

[4] Univ Bologna, Dipartimento Med Specialist Diagnost & Sperimenta, Bologna, Italy

[5] Univ Minnesota, Minneapolis, MN USA

[6] ADC Therapeut America Inc, Clin Dev, Murray Hill, NJ USA

[7] CHU UCL Namur Site Godinne, Dept Hematol, Yvoir, Belgium

来源：

关键词：

D O I：

10.1182/blood-2021-147765

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5